Preview: CROs & CDMOs

CDMOs and CROs are under great pressure to integrate new trial designs and drug formats – including ATMPs, ADCs, condensate blockers, RNA drugs and formulations as well as automated preclinical testing procedures – into their service portfolio, while at the same time facing a global shortage of qualified personnel. In addition to classic antibody and conjugate drugs and various RNA drugs and vaccines, and increasingly to produce cell and gene therapeutics, the first in vivo CRISPR treatments or synthetic peptide hormone combinations are entering the market. On the CRO side, the same is true for cell- and organoid-based drug discovery technologies, new trial designs and AI. Become visible in European Biotechnology’s CDMO & CRO special and present your offerings and portfolio to customers.

Examples of topics

AI-guided cell line selection, process development & upscaling, process monitoring, QbD, single-use equipment, media development, cell culture, glycoengineering, conjugation, formulation, fill & finish, DSP, continuous processing, ex vivo genetic engineering, NK/MAIT/TCR engineering, IgG-like bispecifics, vector technology, plasmid engineering, modular UPS and DSP, antibody engineering, purification, polishing, etc.

Interested in advertising with us? We’re happy to advise you!